English

CEREVEL THERAPEUTICS HOLDINGS, INC.

EDGAR

CERE Quarterly report (10-Q) · filed 2024-05-08

27 filing records in this dataset, filed from 2020-05-19 to 2024-05-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

0 USD

2023 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-342 million USD

2023 · USD

Exact inputs and evidence

Operating Cash Flow: -342301000 USD Source

Free cash flow

-346 million USD

2023 · USD

Exact inputs and evidence

Operating Cash Flow: -342301000 USD Source
Capital Expenditure: 3808000 USD Source

Cash and cash equivalents: 320 million USD 2024-03-31 Source
Exact value

320436000 USD
Long-term debt including current maturities: 375 million USD 2024-03-31 Source
Exact value

375187000 USD
Shares outstanding: 182 million shares 2024-03-31 Source
Exact value

181888631 shares

Reported share-count change

16.03% · 25.1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

156760109 shares · 2023-03-31· Source
181888631 shares · 2024-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-460 million USD

2023-04-01 – 2024-03-31

Exact inputs and evidence

Net income: -99535000 USD · 2023-04-01 – 2023-06-30 Source
Net income: -96361000 USD · 2023-07-01 – 2023-09-30 Source
Net income: -432842000 USD · 2023-01-01 – 2023-12-31 Source
Net income: -300182000 USD · 2023-01-01 – 2023-09-30 Source
Net income: -131912000 USD · 2024-01-01 – 2024-03-31 Source

Operating cash flow

-367 million USD

2023-04-01 – 2024-03-31

Exact inputs and evidence

Operating cash flow: -172250000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -94923000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -244881000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -172250000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -342301000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -244881000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -119669000 USD · 2024-01-01 – 2024-03-31 Source

Capital expenditure

3.74 million USD

2023-04-01 – 2024-03-31

Exact inputs and evidence

Capital expenditure: 2393000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 336000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 2906000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 2393000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 3808000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 2906000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 271000 USD · 2024-01-01 – 2024-03-31 Source

Free cash flow

-371 million USD

2023-04-01 – 2024-03-31

Exact inputs and evidence

Operating cash flow: -172250000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -94923000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -244881000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -172250000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -342301000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -244881000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -119669000 USD · 2024-01-01 – 2024-03-31 Source
Capital expenditure: 2393000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 336000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 2906000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 2393000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 3808000 USD · 2023-01-01 – 2023-12-31 Source
Capital expenditure: 2906000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 271000 USD · 2024-01-01 – 2024-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-05-08.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2023-12-31
Operating income: 5 of 11 periods available· newest 2023-12-31
Net income: 5 of 11 periods available· newest 2023-12-31
Operating cash flow: 5 of 11 periods available· newest 2023-12-31
Capital expenditure: 5 of 11 periods available· newest 2023-12-31
Total assets: 4 of 11 periods available· newest 2023-12-31
Total liabilities: 4 of 11 periods available· newest 2023-12-31
Current assets: 4 of 11 periods available· newest 2023-12-31
Current liabilities: 4 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2023-12-31
Shares outstanding: 4 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2022-01-01 – 2022-12-31
Current period

USD 0

2023-01-01 – 2023-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
0 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2023-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2533509 Filing: 000095017024021078 Input fundies:Revenue: 0 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017023003777/cere-20221231.htm#4661625 Filing: 000095017023003777
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 81.33 million

Prior period

−USD 351.51 million

2022-01-01 – 2022-12-31
Current period

−USD 432.84 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-432842000 − -351511000 = -81331000 USD

-351511000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-432842000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2023-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Year-over-year change in Net income: -81331000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -432842000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#3524439 Filing: 000095017024021078 Input fundies:NetIncome: -351511000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#3525741 Filing: 000095017024021078
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 49.11 million

Prior period

−USD 293.19 million

2022-01-01 – 2022-12-31
Current period

−USD 342.3 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-342301000 − -293187000 = -49114000 USD

-293187000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-342301000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2023-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Year-over-year change in Operating cash flow: -49114000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -342301000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2277610 Filing: 000095017024021078 Input fundies:OperatingCashFlow: -293187000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2279079 Filing: 000095017024021078
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-3.7%

Prior period

USD 3.95 million

2022-01-01 – 2022-12-31
Current period

USD 3.81 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

3808000 − 3954000 = -146000 USD

3954000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
3808000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2023-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Year-over-year change in Capital expenditure: -146000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3808000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2293070 Filing: 000095017024021078 Input fundies:CapitalExpenditure: 3954000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2294528 Filing: 000095017024021078
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 0
Operating costs Derived USD 447.27 million
Operating income −USD 447.27 million
Tax, interest and other Derived −USD 14.42 million
Net income −USD 432.84 million

Cash

Operating cash flow −USD 342.3 million
Capital expenditure USD 3.81 million
Free cash flow Derived −USD 346.11 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	149116000 Derived	-149116000	3026000 Derived	-152142000	-136694000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -149116000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -152142000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -117802000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 18892000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	220098000 Derived	-220098000	5236000 Derived	-225334000	-189049000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -220098000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -225334000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -178546000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 10503000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	367848000 Derived	-367848000	-16337000 Derived	-351511000	-297141000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -367848000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -351511000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -293187000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 3954000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	447265000 Derived	-447265000	-14423000 Derived	-432842000	-346109000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -447265000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -432842000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -342301000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 3808000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2023

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20202020-12-31	Revenue	Revenue: 0 Open source
20212021-12-31	Revenue	Revenue: 0 Open source
20222022-12-31	Revenue	Revenue: 0 Open source
20232023-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -149116000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -220098000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -367848000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -447265000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -152142000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -225334000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -351511000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -432842000 Open source Revenue: 0 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -117802000 Open source Capital Expenditure: 18892000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -178546000 Open source Capital Expenditure: 10503000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -293187000 Open source Capital Expenditure: 3954000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -342301000 Open source Capital Expenditure: 3808000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -342.3M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-117802000	Operating Cash Flow: -117802000 Open source
20212021-12-31	Operating cash flow	-178546000	Operating Cash Flow: -178546000 Open source
20222022-12-31	Operating cash flow	-293187000	Operating Cash Flow: -293187000 Open source
20232023-12-31	Operating cash flow	-342301000	Operating Cash Flow: -342301000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -346.1M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-136694000	Operating Cash Flow: -117802000 Open source Capital Expenditure: 18892000 Open source
20212021-12-31	Free cash flow	-189049000	Operating Cash Flow: -178546000 Open source Capital Expenditure: 10503000 Open source
20222022-12-31	Free cash flow	-297141000	Operating Cash Flow: -293187000 Open source Capital Expenditure: 3954000 Open source
20232023-12-31	Free cash flow	-346109000	Operating Cash Flow: -342301000 Open source Capital Expenditure: 3808000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

45.8% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	13.6%	Total Liabilities: 60753000 Open source Total Assets: 445273000 Open source
20212021-12-31	Liabilities / assets	16%	Total Liabilities: 110190000 Open source Total Assets: 688919000 Open source
20222022-12-31	Liabilities / assets	48.8%	Total Liabilities: 496584000 Open source Total Assets: 1017822000 Open source
20232023-12-31	Liabilities / assets	45.8%	Total Liabilities: 569553000 Open source Total Assets: 1243298000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.92× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	13.22×	Current Assets: 390560000 Open source Current Liabilities: 29548000 Open source
20212021-12-31	Current assets / current liabilities	13.59×	Current Assets: 578017000 Open source Current Liabilities: 42538000 Open source
20222022-12-31	Current assets / current liabilities	12.48×	Current Assets: 905651000 Open source Current Liabilities: 72564000 Open source
20232023-12-31	Current assets / current liabilities	10.92×	Current Assets: 1006938000 Open source Current Liabilities: 92179000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 128.39 million Exact value Exact value: -128389000 USD 2019-01-01 – 2019-12-31: -128389000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2019-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Net Income: -128389000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -128389000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017022002516/cere-20211231.htm#5249709 Filing: 000095017022002516 The citation records this snapshot. The page link may show a newer release later.	−USD 70.72 million Exact value Exact value: -70720000 USD 2019-01-01 – 2019-12-31: -70720000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2019-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Operating Cash Flow: -70720000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70720000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017022002516/cere-20211231.htm#3913321 Filing: 000095017022002516 The citation records this snapshot. The page link may show a newer release later.	USD 1.1 million Exact value Exact value: 1099000 USD 2019-01-01 – 2019-12-31: 1099000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2019-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Capital Expenditure: 1099000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1099000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017022002516/cere-20211231.htm#3929457 Filing: 000095017022002516 The citation records this snapshot. The page link may show a newer release later.	−USD 71.82 million Calculation and evidence -70720000 − 1099000 USD Exact free cash flow: -71819000 USD 2019-01-01 – 2019-12-31: -70720000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1099000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2019-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Free cash flow: -71819000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70720000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017022002516/cere-20211231.htm#3913321 Filing: 000095017022002516 Input fundies:CapitalExpenditure: 1099000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017022002516/cere-20211231.htm#3929457 Filing: 000095017022002516 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 152.14 million Exact value Exact value: -152142000 USD 2020-01-01 – 2020-12-31: -152142000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2020-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Net Income: -152142000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -152142000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017023003777/cere-20221231.htm#6131986 Filing: 000095017023003777 The citation records this snapshot. The page link may show a newer release later.	−USD 117.8 million Exact value Exact value: -117802000 USD 2020-01-01 – 2020-12-31: -117802000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2020-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Operating Cash Flow: -117802000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -117802000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017023003777/cere-20221231.htm#4302403 Filing: 000095017023003777 The citation records this snapshot. The page link may show a newer release later.	USD 18.89 million Exact value Exact value: 18892000 USD 2020-01-01 – 2020-12-31: 18892000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2020-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Capital Expenditure: 18892000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18892000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017023003777/cere-20221231.htm#4326498 Filing: 000095017023003777 The citation records this snapshot. The page link may show a newer release later.	−USD 136.69 million Calculation and evidence -117802000 − 18892000 USD Exact free cash flow: -136694000 USD 2020-01-01 – 2020-12-31: -117802000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 18892000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2020-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Free cash flow: -136694000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -117802000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017023003777/cere-20221231.htm#4302403 Filing: 000095017023003777 Input fundies:CapitalExpenditure: 18892000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017023003777/cere-20221231.htm#4326498 Filing: 000095017023003777 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 225.33 million Exact value Exact value: -225334000 USD 2021-01-01 – 2021-12-31: -225334000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Net Income: -225334000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -225334000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#3527043 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	−USD 178.55 million Exact value Exact value: -178546000 USD 2021-01-01 – 2021-12-31: -178546000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Operating Cash Flow: -178546000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -178546000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2280548 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	USD 10.5 million Exact value Exact value: 10503000 USD 2021-01-01 – 2021-12-31: 10503000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Capital Expenditure: 10503000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10503000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2295986 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	−USD 189.05 million Calculation and evidence -178546000 − 10503000 USD Exact free cash flow: -189049000 USD 2021-01-01 – 2021-12-31: -178546000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 10503000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2021-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Free cash flow: -189049000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -178546000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2280548 Filing: 000095017024021078 Input fundies:CapitalExpenditure: 10503000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2295986 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 351.51 million Exact value Exact value: -351511000 USD 2022-01-01 – 2022-12-31: -351511000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2022-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Net Income: -351511000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -351511000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#3525741 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	−USD 293.19 million Exact value Exact value: -293187000 USD 2022-01-01 – 2022-12-31: -293187000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2022-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Operating Cash Flow: -293187000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -293187000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2279079 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	USD 3.95 million Exact value Exact value: 3954000 USD 2022-01-01 – 2022-12-31: 3954000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2022-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Capital Expenditure: 3954000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3954000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2294528 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	−USD 297.14 million Calculation and evidence -293187000 − 3954000 USD Exact free cash flow: -297141000 USD 2022-01-01 – 2022-12-31: -293187000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 3954000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2022-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Free cash flow: -297141000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -293187000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2279079 Filing: 000095017024021078 Input fundies:CapitalExpenditure: 3954000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2294528 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 432.84 million Exact value Exact value: -432842000 USD 2023-01-01 – 2023-12-31: -432842000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2023-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Net Income: -432842000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -432842000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#3524439 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	−USD 342.3 million Exact value Exact value: -342301000 USD 2023-01-01 – 2023-12-31: -342301000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2023-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Operating Cash Flow: -342301000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -342301000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2277610 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	USD 3.81 million Exact value Exact value: 3808000 USD 2023-01-01 – 2023-12-31: 3808000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2023-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Capital Expenditure: 3808000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3808000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2293070 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.	−USD 346.11 million Calculation and evidence -342301000 − 3808000 USD Exact free cash flow: -346109000 USD 2023-01-01 – 2023-12-31: -342301000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 3808000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CEREVEL THERAPEUTICS HOLDINGS, INC. · 2023-12-31 CEREVEL THERAPEUTICS HOLDINGS, INC. (edgar:1805387) Free cash flow: -346109000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:07:47Z Snapshot: 9818b0f1b79c7ef729782772eea125e0e5532aab562a84b021a5013149593a03 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1805387?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -342301000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2277610 Filing: 000095017024021078 Input fundies:CapitalExpenditure: 3808000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1805387/000095017024021078/cere-20231231.htm#2293070 Filing: 000095017024021078 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

27 filings · 1,098 latest values · 1,098 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001805387, 1805387, CERE, edgar:1805387

Also known as ARYA Sciences Acquisition Corp II, CEREVEL THERAPEUTICS HOLDINGS, INC., Cerevel Therapeutics Holdings, Inc.

CEREVEL THERAPEUTICS HOLDINGS, INC.

Latest fiscal year

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation